Effect of antibiotic treatment on establishment and elimination of intestinal colonization by KPC-producing Klebsiella pneumoniae in mice

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 6, 2011, Pages 2585-2589

  Perez, Federico ^a,c   Pultz, Michael J ^a   Endimiani, Andrea ^a,c   Bonomo, Robert A ^a,b,c   Donskey, Curtis J ^a,b,c  

^a LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^b GERIATRIC RESEARCH EDUCATION AND CLINICAL CENTER   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAPENEMASE; CEFEPIME; CIPROFLOXACIN; CLINDAMYCIN; COLISTIN; ERTAPENEM; GENTAMICIN; KLEBSIELLA PNEUMONIAE CARBAPENEMASE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; UNCLASSIFIED DRUG;

ANAEROBIC BACTERIUM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTEROIDES; CLOSTRIDIUM PERFRINGENS; COLONY FORMING UNIT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME SYNTHESIS; FECES ANALYSIS; FEMALE; INTESTINE FLORA; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT DURATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; FEMALE; INTESTINES; KLEBSIELLA PNEUMONIAE; MICE;

EID: 79956291393     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00891-10     Document Type: Article

References (30)

1. Anderson, K. F., et al. 2007. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J. Clin. Microbiol. 45:2723-2725.
2. Anonymous. 2009. Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb. Mortal. Wkly. Rep. 58:256-260.
3. Bhalla, A., et al. 2003. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. Infect. Control Hosp. Epidemiol. 24:644-649.
4. Brismar, B., C. Edlund, A. S. Malmborg, and C. E. Nord. 1990. Ciprofloxacin concentrations and impact of the colon microflora in patients undergoing colorectal surgery. Antimicrob. Agents Chemother. 34:481-483.
5. CLSI. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
6. de Smet, A. M., et al. 2009. Decontamination of the digestive tract and oropharynx in ICU patients. N. Engl. J. Med. 360:20-31.
7. Donskey, C. J. 2006. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. Clin. Infect. Dis. 43(Suppl. 2):S62-S69.
8. Donskey, C. J., et al. 2000. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. N. Engl. J. Med. 343:1925-1932.
9. Endimiani, A., et al. 2008. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob. Agents Chemother. 52:2680-2682.
10. Endimiani, A., Y. Choudhary, and R. A. Bonomo. 2009. In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob. Agents Chemother. 53:3599-3601.
11. Falagas, M. E., et al. 2007. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case control study. J. Antimicrob. Chemother. 60:1124-1130.
12. Gasink, L. B., P. H. Edelstein, E. Lautenbach, M. Synnestvedt, and N. O. Fishman. 2009. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect. Control Hosp. Epidemiol. 30:1180-1185.
13. Hirsch, E. B., and V. H. Tam. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 65:1119-1125.
14. Hoyen, C. K., N. J. Pultz, D. L. Paterson, D. C. Aron, and C. J. Donskey. 2003. Effect of parenteral antibiotic administration on establishment of intestinal colonization in mice by Klebsiella pneumoniae strains producing extended-spectrum beta-lactamases. Antimicrob. Agents Chemother. 47:3610-3612.
15. Hussein, K., et al. 2009. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect. Control Hosp. Epidemiol. 30:666-671.
16. Kager, L., L. Liljeqvist, A. S. Malmborg, and C. E. Nord. 1981. Effect of clindamycin prophylaxis on the colonic microflora in patients undergoing colorectal surgery. Antimicrob. Agents Chemother. 20:736-740.
17. Kwak, Y. G., et al. 2005. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb. Drug Resist. 11:165-169.
18. Nord, C. E., B. Brismar, B. Kasholm-Tengve, and G. Tunevall. 1993. Effect of piperacillin/tazobactam treatment on human bowel microflora. J. Antimicrob. Chemother. 31(Suppl. A):61-65.
19. Nord, C. E., E. Sillerstrom, and E. Wahlund. 2006. Effect of tigecycline on normal oropharyngeal and intestinal microflora. Antimicrob. Agents Chemother. 50:3375-3380.
20. Nordmann, P., G. Cuzon, and T. Naas. 2009. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect. Dis. 9:228-236.
21. Patel, G., S. Huprikar, S. H. Factor, S. G. Jenkins, and D. P. Calfee. 2008. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect. Control Hosp. Epidemiol. 29:1099-1106.
22. Perez, F., M. J. Pultz, A. Endimiani, R. A. Bonomo, and C. J. Donskey. 2009. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother., abstr. B-1331.
23. Pletz, M. W., et al. 2004. Ertapenem pharmacokinetics and impact on intestinal microflora, in comparison to those of ceftriaxone, after multiple dosing in male and female volunteers. Antimicrob. Agents Chemother. 48:3765-3772.
24. Pultz, M. J., and C. J. Donskey. 2007. Effects of imipenem-cilastatin, ertapenem, piperacillin-tazobactam, and ceftriaxone treatments on persistence of intestinal colonization by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae strains in mice. Antimicrob. Agents Chemother. 51:3044-3045.
25. Pultz, M. J., M. M. Nerandzic, U. Stiefel, and C. J. Donskey. 2008. Emergence and acquisition of fluoroquinolone-resistant gram-negative bacilli in the intestinal tracts of mice treated with fluoroquinolone antimicrobial agents. Antimicrob. Agents Chemother. 52:3457-3460.
26. Queenan, A. M., and K. Bush. 2007. Carbapenemases: the versatile betalactamases. Clin. Microbiol. Rev. 20:440-458.
27. Rice, L. B., et al. 2008. The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 52:3427-3429.
28. Schwaber, M. J., and Y. Carmeli. 2008. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 300:2911-2913.
29. Schwaber, M. J., et al. 2008. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob. Agents Chemother. 52:1028-1033.
30. van Ogtrop, M. L., H. F. Guiot, H. Mattie, and R. van Furth. 1991. Modulation of the intestinal flora of mice by parenteral treatment with broadspectrum cephalosporins. Antimicrob. Agents Chemother. 35:976-982.